eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2019
vol. 5
 
Share:
Send email
Share:
abstract:
Original paper

Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls – PRO-CARDIO-C study

Anna Piekarska
1
,
Aleksandra Mamzer-Dachnowska
2
,
Jarosław D. Kasprzak
2
,
Jan Z. Peruga
2
,
Andrzej Kaszuba
3
,
Aleksandra Berkan-Kawińska
1

  1. Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland
  2. Chair and Department of Cardiology, Medical University of Lodz, Poland
  3. Department of Dermatology, Medical University of Lodz, Poland
Clin Exp HEPATOL 2019; 5, 2: 118–122
DOI: https://doi.org/10.5114/ceh.2019.84782
Online publish date: 2019/05/08
View full text Get citation
 
PlumX metrics:
Aim of the study
Ongoing national screening programmes suggest that the prevalence of chronic hepatitis C (CHC) in Poland ranges between 0.5% and 1%. It has been recently noted that patients with confirmed coronary artery disease may be at higher risk for hepatitis C virus (HCV) infection.

Material and methods
Testing for the presence of anti-HCV antibodies was performed in a group of patients admitted to the Cardiology Department with symptomatic ischemic heart disease (IHD) and in patients hospitalised in the Dermatology Department.

Results
A total of 1171 patients underwent anti-HCV testing: 672 patients in the Cardiology Department (K group) and 499 patients in the Dermatology Department (D group). Twenty-eight (2.4%) positive anti-HCV results were detected. The prevalence of positive anti-HCV antibodies in groups K and D was 2.23% and 2.61%, respectively (p > 0.05). Presence of HCV RNA was confirmed in 15 cases (1.28%) – 7 patients in group K and 8 patients in group D (1.04% and 1.6%, respectively; p > 0.05).

Conclusions
Our findings suggest that this patient cohort has increased risk of HCV infection, which may influence screening strategies.

keywords:

hepatitis C, coronary artery disease, anti-HCV antibody, screening, HCV treatment
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.